- Pfizer raised its full-year Covid vaccine revenue forecast from $26B to $33.5B as demand surges following the Delta variant outbreak.
- Revenues could rise further if US regulators authorize a third booster shot to fight new variants.
- Pfizer also plans on creating a new vaccine formulation designed to fight the Delta variant.
- Rising demand could make Pfizer Covid vaccine one of the best-selling drugs ever, outpacing Merck’s Keytruda cancer treatment.
- Pfizer’s total 2021 revenue is forecast to reach $78-80 billion.
